Abeona Therapeutics Inc. (ABEO)
NASDAQ: ABEO · Real-Time Price · USD
5.60
+0.33 (6.26%)
At close: May 12, 2025, 4:00 PM
5.77
+0.17 (3.04%)
After-hours: May 12, 2025, 6:49 PM EDT
Abeona Therapeutics Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Abeona Therapeutics stock have an average target of 18, with a low estimate of 15 and a high estimate of 21. The average target predicts an increase of 221.43% from the current stock price of 5.60.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Abeona Therapeutics stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 3 | 3 | 3 |
| Buy | 1 | 1 | 1 | 1 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 4 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $15 → $20 | Strong Buy | Maintains | $15 → $20 | +257.14% | Apr 30, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +167.86% | Mar 24, 2025 |
| Oppenheimer | Oppenheimer | Buy Initiates $16 | Buy | Initiates | $16 | +185.71% | Mar 5, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +167.86% | Feb 19, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +167.86% | Nov 25, 2024 |
Financial Forecast
Revenue This Year
12.53M
Revenue Next Year
80.18M
from 12.53M
Increased by 539.93%
EPS This Year
-0.31
from -1.55
EPS Next Year
-0.19
from -0.31
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 15.8M | 111.8M | 230.4M | ||
| Avg | 12.5M | 80.2M | 157.8M | ||
| Low | 8.8M | 55.9M | 93.1M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 792.6% | 187.3% | ||
| Avg | - | 539.9% | 96.8% | ||
| Low | - | 345.8% | 16.1% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 1.86 | -0.08 | 1.54 | ||
| Avg | -0.31 | -0.19 | 0.40 | ||
| Low | -1.41 | -0.41 | -0.61 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.